Drug Trial Radar · NCT06775041
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Jan 13, 2025
Primary completion
Mar 30, 2026
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- PRG Science & Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take the standard of care (SOC), lonafarnib, and will be randomized to either take SOC alone or in combination with progerinin.
Conditions
- Hutchinson-Gilford Progeria Syndrome
Interventions
ProgerininDrug
Dosing will be determined based on body weight. Dosing ranges from 500mg to 1500mg daily. Progerinin is available in sachets of 250 mg or 350 mg for oral use.
LonafarnibDrug
Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in plasma progerin concentrationTime frame: Baseline and Month 4 of each cohort
- Incidence of Dose Limiting Toxicities (DLTs)Time frame: From baseline to follow-up (approximately 13 months)
- Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)Time frame: From baseline to follow-up (approximately 13 months)
- Incidence of withdrawals due to Adverse Events (AEs)Time frame: From baseline to follow-up (approximately 13 months)
- Incidence of Treatment-Related Adverse EventsTime frame: From baseline to follow-up (approximately 13 months)
- Incidence of Serious Adverse Events (SAEs)Time frame: From baseline to follow-up (approximately 13 months)
- Change/shifts in laboratory values from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Change in blood pressure from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Change in heart rate from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Change in respiratory rate from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Change in temperature from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Change in Electrocardiogram (ECG) parameter, ventricular rate (beats per minute), from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Change in Electrocardiogram (ECG) parameter, PR interval (msec), from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Change in Electrocardiogram (ECG) parameter, QRS interval (msec), from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Change in Electrocardiogram (ECG) parameter, QT interval (msec), from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Change in Electrocardiogram (ECG) parameter, QTc interval (msec), from baselineTime frame: From baseline to follow-up (approximately 13 months)
- Maximum observed plasma drug concentration (Cmax)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of each cohort
- Apparent terminal elimination half-life (t1/2)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2
- Time to maximum observed plasma drug concentration (Tmax)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2
- Area under the plasma drug concentration-time curve (AUC) from time 0 to the end of the dosing period (AUC0-τ)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2
- Clearance (CL)Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2
- Covariates: AgeTime frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of each cohort
- Covariates: Body weightTime frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of each cohort
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Boston Children's Hospital
Boston, Massachusetts
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.